Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.47 |
| ▸ | LCK | P06239 | 5/20 | 0.46 |
| ▸ | KDR | P35968 | 5/20 | 0.46 |
| ▸ | JAK3 | P52333 | 5/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.46 |
| ▸ | TEK | Q02763 | 3/20 | 0.46 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.42 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22680062 | 0.89 | WNT3A (0.50) | DGAT2TRPV1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL24571214 | 0.86 | TRPV1 (0.49) | BRAFKDRDGAT2TRPV1NPC1 | |
| SCHEMBL22659373 | 0.85 | BRAF (0.47) | BRAFLCKKDRJAK3MAPK14 | |
| SCHEMBL22680041 | 0.82 | PTPN1 (0.56) | DGAT2TRPV1NPC1RAB9AMAPT | |
| SCHEMBL29405064 | 0.77 | DGAT2 (0.49) | BRAFDGAT2TRPV1DDR2MAPT | |
| SCHEMBL22659359 | 0.77 | DGAT2 (0.49) | BRAFDGAT2TRPV1DDR2MAPT | |
| SCHEMBL22659137 | 0.75 | KCNQ3 (0.47) | BRAFKDRDGAT2TRPV1NPC1 | |
| SCHEMBL22659283 | 0.73 | TRPV1 (0.48) | KDRDGAT2TRPV1MAPTSMN1; SMN2 | |
| SCHEMBL22659169 | 0.73 | KCNJ11 (0.47) | BRAFLCKKDRJAK3MAPK14 | |
| SCHEMBL22659056 | 0.73 | KCNQ3 (0.50) | KDRTRPV1NPC1RAB9AKCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| WO-2020231739-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | AHR, ARNT, HMOX1 | BRAF 1104/4885LCK 1227/4885KDR 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.